Finance

Lists
Why is ARGX up २.५३%?
Dive Deeper
ARGX:NASDAQ
argenx SE - ADR
US$ ९३५.९५
+२.५३%
(+२३.०८) 1D
अक्टोबर ६, १३:०२:४७ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARGX...
Open
US$ ९२२.३९
High
US$ ९४२.३५
Low
US$ ९०९.९४
Mkt. cap
५८.८७ अरब
Avg. vol.
२.५६ लाख
Volume
३.०१ लाख
P/E ratio
३५.५६
52-wk high
US$ १,०७२.७५
52-wk low
US$ ६६१.८५
EPS
US$ २६.३२
Beta
०.४५
Shares outstanding
६.२६ करोड
No. of employees
२ हजार
Open
US$ ९२२.३९
High
US$ ९४२.३५
Low
US$ ९०९.९४
Mkt. cap
५८.८७ अरब
Avg. vol.
२.५६ लाख
Volume
३.०१ लाख
P/E ratio
३५.५६
52-wk high
US$ १,०७२.७५
52-wk low
US$ ६६१.८५
EPS
US$ २६.३२
Beta
०.४५
Shares outstanding
६.२६ करोड
No. of employees
२ हजार
News stories
From web sources and news partners
AD HOC NEWS
AD HOC NEWS
·
३० मिनेट पहिले
argenx stock: New VYVGART data span myasthenia gravis and CIDP
AD HOC NEWS
AD HOC NEWS
·
२० घण्टा पहिले
Argenx stock gets fresh VYVGART data before Q3 results
Yahoo Finance UK
Yahoo Finance UK
·
१ दिन पहिले
BMY or ARGX: Which Is the Better Value Stock Right Now?
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About argenx SE - ADR
CEO-
Employees१.८६ हजार
Founded२००८ अप्रिल २५
Headquarters-
Sector-
Websiteargenx.com
Analyst ratings
Based on 21 analysts giving stock ratings to ARGX in the past 3 months
Strong buy
Buy
20
Hold
1
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for ARGX in the last 3 months.
Highest
Current US$ ९३५.९५
US$ १,४१५.०० (+५१.१८%)
Average
US$ १,१८२.५८ (+२६.३५%)
Lowest
US$ ९३२.०० (-०.४२%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
09/29/2026
Unknown Analyst
Jefferies
Buy
Maintained
US$ १,२१५.००
+२९.८%
09/15/2026
David Nierengarten
Wedbush
Buy
Maintained
US$ १,१५०.००
+२२.९%
09/03/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/02/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
US$ १,२५०.००
+३३.६%
09/01/2026
Derek Archila
Wells Fargo
Buy
Reiterated
US$ १,४१५.००
+५१.२%
08/26/2026
Xian Deng
UBS
Buy
Upgraded
US$ १,४००.००
+४९.६%
08/26/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
US$ १,२०२.००
+२८.४%
08/24/2026
Luca Issi
RBC Capital
Buy
Maintained
US$ १,१००.००
+१७.५%
08/17/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
US$ १,१००.००
+१७.५%
08/18/2026
Danielle Brill
Truist Financial
Buy
Maintained
US$ १,०९५.००
+१७%
08/18/2026
Jason Butler
Citizens JMP
Buy
Maintained
US$ १,२००.००
+२८.२%
08/18/2026
Samantha Semenkow
Citi
Buy
Maintained
US$ १,३०१.००
+३९%
08/18/2026
Yaron Werber
TD Cowen
Buy
Reiterated
US$ १,३५३.००
+४४.६%
08/17/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
US$ १,२१५.००
+२९.८%
08/17/2026
Yatin Suneja
Guggenheim
Buy
Initiated
US$ १,१८५.००
+२६.६%
08/04/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
US$ १,२८२.००
+३७%
07/28/2026
Unknown Analyst
Wedbush
Buy
Maintained
US$ १,०५०.००
+१२.२%
07/28/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
US$ १,०५९.००
+१३.१%
07/27/2026
Colleen M. Kusy
Robert W. Baird
Hold
Maintained
US$ ९३२.००
-०.४%
07/27/2026
James Gordon CFA
Barclays
Buy
Maintained
US$ ९५०.००
+१.५%
07/24/2026
Thomas Smith
Leerink Partners
Buy
Maintained
US$ १,०६५.००
+१३.८%
07/24/2026
Myles Minter
William Blair
Buy
Maintained
-
-
06/24/2026
Unknown Analyst
William O'Neil
Buy
Initiated
-
-
06/08/2026
Rajan Sharma
Goldman Sachs
Buy
Maintained
US$ ९१०.००
-२.८%
02/26/2026
Last report
२०२६ जुलाई २३
Fiscal period
Q2 2026
EPS / Est. (USD)
US$ ७.३२ / US$ ६.५२
+१२.३२%beat
Revenue / Est. (USD)
१.५४ अरब / १.४४ अरब
+६.८२%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१.१५ अरब
१.३१ अरब
१.३१ अरब
१.५४ अरब
Cost of goods sold
४६.५१ करोड
५२.१४ करोड
५६.४० करोड
६३.१० करोड
Cost of revenue
४६.५१ करोड
५२.१४ करोड
५६.४० करोड
६३.१० करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
३३.६३ करोड
४२.९६ करोड
३५.५० करोड
४१.७० करोड
Operating expense
३३.६३ करोड
४२.९६ करोड
३५.५० करोड
४१.७० करोड
Total operating expenses
८०.१४ करोड
९५.१० करोड
९१.९० करोड
१.०५ अरब
Operating income
३५.०० करोड
३५.९६ करोड
३९.४० करोड
४९.३० करोड
Other non operating income
-
-९.०७ लाख
-
-१०.०० लाख
EBT including unusual items
३८.६१ करोड
४०.३३ करोड
४२.६० करोड
५३.१० करोड
EBT excluding unusual items
३८.६१ करोड
३९.१७ करोड
४२.६० करोड
५३.१० करोड
Income tax expense
४.१८ करोड
-१२.९७ करोड
६.०० करोड
५.९० करोड
Effective tax rate
१०.८३%
-३२.१५%
१४.०८%
११.११%
Other operating expenses
-
-
-
-
Net income
३४.४३ करोड
५३.३० करोड
३६.६० करोड
४७.२० करोड
Net profit margin
२९.९०%
४०.६७%
२७.८८%
३०.६३%
Earnings per share
५.१८
८.०२
५.५२
७.३२
Interest and investment income
४.२७ करोड
४.५० करोड
४.४० करोड
४.८० करोड
Interest expense
-९.९३ लाख
-
-१०.०० लाख
-१०.०० लाख
Net interest expenses
४.१७ करोड
४.५० करोड
४.३० करोड
४.७० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
३५.०४ करोड
३६.१४ करोड
३९.५८ करोड
५०.१५ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू